Covered recipient · General Payments record
DAVID TURBAY
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$26,830.03
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,475.00 | 19 |
| Food and Beverage | $3,355.03 | 135 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $10,552.36 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,920.87 | 26 |
| Amgen Inc. | $3,147.18 | 11 |
| Lilly USA, LLC | $1,125.00 | 1 |
| Abbott Laboratories | $882.18 | 20 |
| Novartis Pharmaceuticals Corporation | $336.43 | 41 |
| E.R. Squibb & Sons, L.L.C. | $154.43 | 11 |
| Aziyo Biologics, Inc. | $143.29 | 1 |
| Novo Nordisk Inc | $137.23 | 3 |
| Actelion Pharmaceuticals US, Inc. | $73.99 | 3 |
| PFIZER INC. | $73.50 | 4 |
| BIOTRONIK INC. | $72.36 | 1 |
| Merck Sharp & Dohme Corporation | $47.72 | 3 |
| Esperion Therapeutics, Inc. | $36.91 | 2 |
| Medtronic, Inc. | $36.12 | 2 |
| Alnylam Pharmaceuticals Inc. | $25.38 | 1 |
| ABIOMED | $19.11 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.09 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $14.88 | 1 |
| Bardy Diagnostics, Inc. | $12.00 | 1 |
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID TURBAY
NPI 1922082411 · CMS profile ID 132729
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
EL PASO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID TURBAY, NPI 1922082411, CMS profile ID 132729. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID TURBAY, NPI 1922082411, CMS profile ID 132729. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID TURBAY, NPI 1922082411, CMS profile ID 132729, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $26,830.03 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $28.33 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815475223 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.52 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696430 | CMS |
| Novartis Pharmaceuticals Corporation | $7.28 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326803 | CMS |
| PFIZER INC. | $19.01 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832657663 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 04/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834339135 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.32 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834345403 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.50 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834330677 | CMS |
| Abbott Laboratories | $115.39 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815462703 | CMS |
| Novartis Pharmaceuticals Corporation | $7.14 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326795 | CMS |
| Novartis Pharmaceuticals Corporation | $5.71 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326799 | CMS |
| Esperion Therapeutics, Inc. | $15.87 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838426317 | CMS |
| Novartis Pharmaceuticals Corporation | $8.11 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326791 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.72 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783591627 | CMS |
| Abbott Laboratories | $93.91 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818456565 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2.11 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696432 | CMS |
| Novartis Pharmaceuticals Corporation | $5.30 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326787 | CMS |
| ABIOMED | $19.11 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848773617 | CMS |
| Amgen Inc. | $13.32 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825264347 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 03/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696440 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6.05 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696434 | CMS |
| Abbott Laboratories | $15.42 | 03/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818439423 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 03/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696442 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.17 | 03/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783591619 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834324649 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834339083 | CMS |
| PFIZER INC. | $17.77 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832722099 | CMS |
| Novartis Pharmaceuticals Corporation | $6.48 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326783 | CMS |
| Merck Sharp & Dohme Corporation | $18.85 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848332991 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.30 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783591615 | CMS |
| Actelion Pharmaceuticals US, Inc. | $19.18 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788824529 | CMS |
| Novartis Pharmaceuticals Corporation | $7.37 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326775 | CMS |
| Novartis Pharmaceuticals Corporation | $4.86 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326779 | CMS |
| Esperion Therapeutics, Inc. | $21.04 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838426311 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.97 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696436 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.85 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783591611 | CMS |
| Novartis Pharmaceuticals Corporation | $4.33 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326763 | CMS |
| Novartis Pharmaceuticals Corporation | $7.82 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326771 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 02/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834345381 | CMS |
| Actelion Pharmaceuticals US, Inc. | $26.39 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788824531 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 02/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834326531 | CMS |
| Novartis Pharmaceuticals Corporation | $7.67 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326767 | CMS |
| PFIZER INC. | $19.77 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832685439 | CMS |
| Abbott Laboratories | $32.81 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818404789 | CMS |
| Abbott Laboratories | $70.89 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818404791 | CMS |
| Novartis Pharmaceuticals Corporation | $7.87 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326759 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.93 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783591603 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.92 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763696438 | CMS |
| Novartis Pharmaceuticals Corporation | $7.48 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326755 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.35 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834337599 | CMS |
| Novartis Pharmaceuticals Corporation | $7.70 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813326751 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,255.68 | 6 |
| PY2025 | Principal investigator | $782,981.43 | 20 |
| PY2024 | Recipient | $45,690.96 | 2 |
| PY2024 | Principal investigator | $348,978.33 | 7 |
| PY2023 | Recipient | $14,566.16 | 1 |
| PY2023 | Principal investigator | $268,122.92 | 6 |
| PY2022 | Principal investigator | $101,130.75 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
26 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,702.05 | 11/05/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185546568 |
| Recipient | Amgen Inc. | $496.39 | 09/09/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246637278 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,467.20 | 08/26/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190309408 |
| Principal investigator 1 | Amgen Inc. | $20,860.47 | 08/06/2025 | Non-covered Recipient Entity DAVID TURBAY, MD, PLLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246640649 |
| Recipient | Amgen Inc. | $261.00 | 07/31/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246637276 |
| Recipient | Amgen Inc. | $435.00 | 07/31/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | No dispute reported | 06/30/2026 | 1246637282 |
| Principal investigator 1 | Amgen Inc. | $8,701.58 | 07/24/2025 | Non-covered Recipient Entity DAVID TURBAY, MD, PLLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246640647 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $454.28 | 07/15/2025 | Non-covered Recipient Entity DAVID TURBAY MD PLLC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190312201 |
| Recipient | Amgen Inc. | $145.00 | 06/30/2025 | Covered Recipient Physician | MARITIME-CV Ph3 ASCVD Outcomes Trial | No dispute reported | 06/30/2026 | 1246637284 |
| Principal investigator 1 | Amgen Inc. | $99,433.50 | 06/26/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246641115 |
| Principal investigator 1 | Amgen Inc. | $106,545.00 | 06/26/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246641141 |
| Recipient | Amgen Inc. | $270.00 | 06/23/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | No dispute reported | 06/30/2026 | 1246637280 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,488.00 | 06/23/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185546561 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $87,427.60 | 05/09/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185546563 |
| Principal investigator 1 | Amgen Inc. | $12,662.10 | 04/24/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246641101 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $35,883.65 | 03/31/2025 | Non-covered Recipient Entity DAVID TURBAY, MD, PLLC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190308398 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $91,491.40 | 03/14/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function | No dispute reported | 06/30/2026 | 1185546565 |
| Recipient | Amgen Inc. | $3,648.29 | 02/22/2025 | Covered Recipient Physician | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) | No dispute reported | 06/30/2026 | 1246637274 |
| Principal investigator 1 | AstraZeneca UK Limited | $107,860.90 | 02/07/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185546571 |
| Principal investigator 1 | Amgen Inc. | $2,598.24 | 02/06/2025 | Non-covered Recipient Entity DAVID TURBAY, MD, PLLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246640645 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $30,320.50 | 02/04/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190310216 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $54,955.00 | 02/04/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190310222 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,330.55 | 01/30/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190310210 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,569.29 | 01/24/2025 | Non-covered Recipient Entity DAVID TURBAY MD PLLC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190312199 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $55,797.08 | 01/20/2025 | Non-covered Recipient Entity DAVID TURBAY MD PLLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190312197 |
| Principal investigator 1 | Amgen Inc. | $433.04 | 01/15/2025 | Non-covered Recipient Entity DAVID TURBAY, MD | OCEAN(a)-Outcomes Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Outcomes trial | No dispute reported | 06/30/2026 | 1246640651 |